Our Global Health entity is committed to improving access to healthcare for the most vulnerable people living in low- and middle-income countries. Working hand in hand with partners we provide sustainable solutions for unmet medical needs with a focus on infectious diseases like malaria, tuberculosis and neglected tropical diseases, and non-communicable diseases such as diabetes, cardiovascular diseases and mental disorders.

www.sanofi.com

54, rue La Boétie75008 Paris – France

Malaria is a life threatening disease caused by parasites called Plasmodium that are transmitted to people through the bites of infected female Anopheles mosquitoes. Malaria is a preventable and curable disease, but stays the 4th cause of death among communicable diseases in low-income countries(1).

• Plasmodium falciparum is the most prevalent malaria parasite in the African region, accounting for 99.7% of estimated malaria cases in 2018. The risk of death is mainly driven by Plasmodium falciparum.

• Plasmodium vivax is the predominant parasite in Americas, representing 74.1% of the cases. It is also well represented in South-east Asia and Western Pacific. Plasmodium vivax is especially challenging to eliminate because it can persist and cause relapses in infected individuals weeks or months after the original infection. Each subsequent relapse results in incremental morbidity and a higher risk of mortality.

IN 2018, A CHILD WAS STILL DYING FROM MALARIAEVERY 2 MINUTES

228 million cases in 2018(2)

References: 1. Global Health Estimates 2016: Deaths by Cause, Age, Sex, by Country and by Region, 2000-2016.

Geneva, World Health Organization; 2018. https://www.who.int/en/news-room/fact-sheets/detail/ the-top-10-causes-of-death/ – Accessed on October 15th 2019.

2. World malaria report 2019. Geneva: World Health Organization; 2019. Licence: CC BY-NC-SA 3.0 IGO. https://www.who.int/publications-detail/world-malaria-report-2019 – Accessed on April 29th 2020.

of children under 5 account for all malaria deaths(2)

67%

405,000 deaths in 2018(2)

CONTACT USSanofi_Global_Health@sanofi.com

MALARIASANOFI GLOBAL HEALTH

IMPROVING ACCESS TO HEALTHCARE

FOR THE MOST VULNERABLE

De

sign

ed

an

d p

rod

uc

t b

y a

c-s

an

te.c

om

– M

AT-

GLB

-200

0381

– 0

7/20

20. C

ove

r: ©H

ima

rkle

y_G

ett

y Im

ag

es.

Despite signifi cant multisectoral efforts, malaria remains a challenge in many endemic countries.

For decades, Sanofi has played a key role in fi ghting malariain low and middle-income countries with a comprehensive range of drugs and effi cient disease awareness programs. Concretely, Sanofi :

• Continues to provide an hemi-synthetic quality assured artemisinin-based combination therapy (ACT) with a sustainable pricing and safety stock for all patients with uncomplicated Plasmodium falciparum malaria infection.

• Develops a primaquine formulation suitable to children.

• Provides the fi rst prequalifi ed artemether injectable for patients with severe malaria not having access to fi rst line treatment.

• Strengthens disease awareness efforts with innovative and effi cient programs and tools targeting children.

WHATSANOFI DOES

FOCUS ON

MOSKI® MEMORY,the educational digital game created by Sanofi to help combat malaria

Sanofi has started digitalizing its range of learning tools to educate a larger number of children. MOSKI® MEMORY is an online memory game accessible via computer that is suitable for children six years and older. The new tool, graphically consistent with the entire MOSKI KIT® range, was developed to adapt learning methods to societies evolution especially new generation.

It comes in addition to the MOSKI TOON® a dedicated cartoon disseminated on TV and YouTube.

Children are the primary victims of malaria and they are excellent ambassadors for sharing new knowledge with their families and communities.

We must invest in raising public awareness and commitment, improving prevention to combat malaria. Beyond its value in educating children about the disease,MOSKI material shows how we can protect ourselves. Its digitalformat is well-adapted to today’s society.

Dr. Amy Fall-Ndao,Sanofi Global Health Regional Medical Lead Africa

Discoverour program

FOCUS ON

©Ze

ljko

san

trac

/Ge

ttyIm

ag

es

©Ré

mi D

uh

am

el /

Ima

ge

In

Watch the MOSKI TOON®

Play to MOSKI®

MEMORY

MAKING PRIMAQUINE AVAILABLEFOR MORE PATIENTS

Sanofi plans to extend the primaquine forms available for patients in order to answer some gaps such as:

• New dispersible formulation and new dosages to allow the treatment of patients with lower weight.

• Exploring the possibility to extend the indication of primaquine in Plasmodium falciparum transmission blocking.